NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for NUVA
50.55
May 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 32.04 - 51.25
Open     -
Vol / Avg. 0.00/757,450.00
Mkt cap 2.44B
P/E 78.70
Div/yield     -
EPS 0.64
Shares 48.36M
Beta 0.96
Inst. own 103%
Jul 27, 2015
Q2 2015 NuVasive Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 30, 2015
NuVasive�, Inc. at the Nasdaq 32nd Investor Program - 4:30AM EDT - Add to calendar
Jun 12, 2015
NuVasive Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
Jun 10, 2015
NuVasive Inc at Goldman Sachs Healthcare Conference - 11:40AM EDT - Add to calendar
Jun 1, 2015
NuVasive Inc at Jefferies Global Healthcare Conference - 8:00AM EDT - Add to calendar
May 19, 2015
NuVasive�, Inc. at the UBS Global Healthcare Conference - Webcast
May 12, 2015
NuVasive�, Inc. at the Bank of America 2015 Healthcare Conference - Webcast
May 4, 2015
Q1 2015 NuVasive Inc Earnings Call - Webcast
May 4, 2015
Q1 2015 NuVasive Inc Earnings Release
Mar 12, 2015
NuVasive Inc at Barclays Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 16.32% -2.29%
Operating margin 28.88% 2.38%
EBITD margin - 16.36%
Return on average assets 9.54% -1.39%
Return on average equity 19.54% -2.71%
Employees 1,500 -
CDP Score - -

Address

7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NuVasive, Inc. is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is product portfolio is focused on applications for spine fusion surgery, including biologics. Its principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS). The product platform includes its software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system, and a variety of specialized implants. Its biologic product line offerings used to aid the spinal fusion process or bone healing include allograft (donated human tissue), Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, FormaGraft, a collagen synthetic product, and AttraX, a synthetic bone graft material.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Patrick W. G. Miles President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Chief Accounting Officer
Age: 36
Bio & Compensation  - Reuters
Jason M. Hannon Executive Vice President - Corporate Development, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link Executive Vice President - U.S. Sales
Age: 40
Bio & Compensation  - Reuters
Mike Paolucci Executive Vice President - Global Human Resources
Age: 54
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - Strategy and Corporate Communications
Age: 50
Bio & Compensation  - Reuters
Russell Powers Executive Vice President - International
Age: 45
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 72
Bio & Compensation  - Reuters
Peter C. Farrell Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters